IRAK4-IN-15 (compound 35) 是一种有效的选择性IRAK4抑制剂，IC50为 0.002 μM。IRAK4-IN-15 显示出良好的人类 PK 预测且具有低内在清除率。IRAK4-IN-15 与 Acalabrutinib 联用显示出对 MyD88/CD79 双突变体 ABC-DLBCL 的显著协同体外活性。

IRAK4-IN-15 (compound 35) is a potent and selective IRAK4 inhibitor with an IC 50 of 0.002 μM. IRAK4-IN-15 shows good human PK predictions with low intrinsic clearance. IRAK4-IN-15 shows great synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib. [1].

IRAK4-IN-15 (compound 35) shows cell pIRAK4 potencies with an IC 50 of 0.21 μM [1]. IRAK4-IN-15 (compound 35) shows selectivity with IC 50 s of 0.002,1.2, >10,1.5, 0.23, 0.48, 0.93, 0.57 μM for IRAK4, IRAK1, BTK, Flt3, PI3Kδ, TRKa, TRKb, TRKc, respectively [1].

2667681-85-6

C25H29FN10

488.56

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years